PubRank

Cliona M Rooney

Author PubWeight™ 211.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008 11.49
2 CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011 6.38
3 Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011 6.14
4 Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2009 4.98
5 Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006 4.42
6 Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood 2004 4.01
7 Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007 3.94
8 Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011 3.82
9 Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2013 3.65
10 Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004 3.57
11 Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009 3.27
12 A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005 3.18
13 Improving T cell therapy for cancer. Annu Rev Immunol 2007 3.10
14 An inducible caspase 9 safety switch for T-cell therapy. Blood 2005 2.93
15 Post-transplant lymphoproliferative disorders. Annu Rev Med 2005 2.82
16 T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009 2.79
17 T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006 2.68
18 Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007 2.50
19 Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009 2.47
20 Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007 2.33
21 Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013 2.13
22 Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007 2.11
23 Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010 2.06
24 Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002 1.98
25 Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013 1.95
26 Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2002 1.89
27 Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002 1.89
28 Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011 1.87
29 Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010 1.81
30 Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006 1.75
31 Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 2004 1.72
32 Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012 1.72
33 Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 2011 1.72
34 Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2007 1.70
35 Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res 2011 1.70
36 Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma 2010 1.64
37 Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 2007 1.58
38 The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis 2003 1.57
39 Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004 1.57
40 Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 2004 1.56
41 Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003 1.55
42 Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 2003 1.54
43 Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. J Immunother 2009 1.52
44 Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2008 1.52
45 Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010 1.50
46 In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma 2006 1.46
47 Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010 1.44
48 Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol 2005 1.42
49 Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother 2005 1.41
50 Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002 1.40
51 Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 2009 1.40
52 Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009 1.39
53 Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013 1.38
54 Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010 1.38
55 Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother 2003 1.37
56 T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012 1.36
57 Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 2009 1.36
58 Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005 1.36
59 Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005 1.36
60 The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother 2004 1.35
61 Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009 1.35
62 Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008 1.33
63 Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother 2009 1.32
64 PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther 2011 1.32
65 Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005 1.30
66 High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 2011 1.29
67 Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol 2005 1.28
68 Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012 1.27
69 Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 2008 1.25
70 T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther 2010 1.17
71 Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res 2002 1.15
72 Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005 1.13
73 Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother 2007 1.08
74 Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant 2004 1.07
75 Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. J Virol 2003 1.06
76 Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 2012 1.06
77 Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol 2002 1.06
78 Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother 2012 1.04
79 Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther 2011 1.03
80 A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther 2004 1.02
81 Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother 2007 1.01
82 Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy 2011 1.00
83 Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood 2012 1.00
84 Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy 2012 0.98
85 Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp 2011 0.98
86 IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol 2010 0.97
87 Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet 2011 0.97
88 Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther 2011 0.97
89 Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res 2007 0.96
90 Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006 0.96
91 Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother 2006 0.95
92 Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 2003 0.95
93 An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol 2008 0.94
94 Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther 2012 0.94
95 Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J Immunother 2013 0.94
96 Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy 2010 0.94
97 A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther 2010 0.92
98 Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother 2003 0.91
99 Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J Immunother 2008 0.91
100 Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 2010 0.91
101 Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother 2013 0.90
102 Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002 0.89
103 Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 2006 0.89
104 Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother 2009 0.89
105 Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica 2012 0.89
106 Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist 2003 0.89
107 Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies. Transfusion 2008 0.88
108 Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother 2014 0.88
109 Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res 2002 0.88
110 Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother 2008 0.87
111 Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant 2011 0.87
112 A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2- donors. Biol Blood Marrow Transplant 2004 0.86
113 Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol Ther 2007 0.86
114 Enhancement of dendritic cells as vaccines for cancer. Immunotherapy 2010 0.86
115 Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant 2006 0.86
116 Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest 2016 0.85
117 HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol 2005 0.85
118 Improving T cell therapy for cancer. Expert Opin Biol Ther 2006 0.84
119 Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy 2010 0.84
120 Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol 2003 0.84
121 Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother 2014 0.84
122 Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 2004 0.82
123 Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002 0.82
124 In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye. Appl Opt 2008 0.81
125 piggyBac transposon system modification of primary human T cells. J Vis Exp 2012 0.80
126 Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma 2006 0.80
127 Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol 2004 0.80
128 Adoptive immunotherapy for Hodgkin's lymphoma. Int J Hematol 2006 0.78
129 Hitchhiker's guide to the T cell. Nat Med 2005 0.78
130 Immunotherapy to reconstitute immunity to DNA viruses. Semin Hematol 2002 0.77
131 Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program. Transfusion 2014 0.77
132 Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer 2011 0.75
133 Adenovirus immunity: X marks the spot. Mol Ther 2012 0.75
134 What influence has B-cell depletion on viral infections? Leuk Lymphoma 2007 0.75
135 Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. Acta Haematol 2003 0.75